Growth Metrics

Edwards Lifesciences (EW) Common Equity (2016 - 2026)

Edwards Lifesciences has reported Common Equity over the past 17 years, most recently at $10.3 billion for Q4 2025.

  • For Q4 2025, Common Equity rose 3.39% year-over-year to $10.3 billion; the TTM value through Dec 2025 reached $10.3 billion, up 3.39%, while the annual FY2025 figure was $10.3 billion, 3.39% up from the prior year.
  • Common Equity for Q4 2025 was $10.3 billion at Edwards Lifesciences, up from $10.2 billion in the prior quarter.
  • Over five years, Common Equity peaked at $10.6 billion in Q2 2025 and troughed at $4.7 billion in Q1 2021.
  • A 5-year average of $7.3 billion and a median of $6.6 billion in 2023 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: fell 0.5% in 2022 and later soared 48.8% in 2024.
  • Year by year, Common Equity stood at $5.8 billion in 2021, then decreased by 0.5% to $5.8 billion in 2022, then increased by 15.72% to $6.7 billion in 2023, then soared by 48.8% to $10.0 billion in 2024, then rose by 3.39% to $10.3 billion in 2025.
  • Business Quant data shows Common Equity for EW at $10.3 billion in Q4 2025, $10.2 billion in Q3 2025, and $10.6 billion in Q2 2025.